Showing 481 - 500 results of 2,004 for search '"Breast cancer"', query time: 0.06s Refine Results
  1. 481

    Menopausal Hormone Therapy: Its Role in the Prevention of Cardiovascular Diseases and the Risk of Breast Cancer in Women by Tam Thai Thanh Tran, Thu Minh Phung, Anh Thi Mai Do, Quynh Tran Mai Ly, Tin Hoang Nguyen

    Published 2025-01-01
    “…However, estrogen metabolism plays a crucial role in the genotoxic pathway that leads to breast cancer. Moreover, MHT is associated with cell proliferation and mutation signaling pathways in breast cancer, as well as the process of growing the breast cancer stem cell. …”
    Get full text
    Article
  2. 482

    Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient by Nu T. Lu, Jeffrey Raizer, Erwin P. Gabor, Natalie M. Liu, James Q. Vu, Dennis J. Slamon, John L. Barstis

    Published 2015-09-01
    “…We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination therapy with intravenous (IV) trastuzumab. …”
    Get full text
    Article
  3. 483
  4. 484
  5. 485

    Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis by Chih-Ning Cheng, Yun-Jung Tsai, Huai-Hsuan Chiu, Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Sheng Lu, Ching-Hua Kuo

    Published 2025-01-01
    “…The BEEP regimen, comprising bevacizumab, etoposide, and cisplatin, has recently demonstrated promising clinical outcomes for patients with breast cancer brain metastasis (BCBM) or leptomeningeal metastasis (LM). …”
    Get full text
    Article
  6. 486
  7. 487
  8. 488
  9. 489
  10. 490

    Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer by Hanghang Ma, Jianbin Li

    Published 2025-02-01
    “…Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against breast cancer. Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing HER2, there is still controversy over options after ADCs. …”
    Get full text
    Article
  11. 491
  12. 492
  13. 493

    Digital humanistic program to manage premature frailty in young breast cancer survivors with gender perspective by Yun Hu, Joshua Wiley, Lulu Jiang, Xiyi Wang, Ran Yi, Jiehui Xu, Yanyan Liu, Aozhou Weng, Futai Zou, Eun-Ok Im

    Published 2025-01-01
    “…Abstract Premature frailty is a critical challenge for young breast cancer survivors (YBCSs), impacting their health and perpetuating gender inequality through heightened vulnerability and marginalization. …”
    Get full text
    Article
  14. 494

    The Role of Oral Fusobacterium nucleatum in Female Breast Cancer: A Systematic Review and Meta-Analysis by Fariah I. Gaba, Raquel Carcelén González, Raquel González Martïnez

    Published 2022-01-01
    “…Introduction. Breast cancer is the world’s most prevalent malignancy, with an increasing incidence and a predisposition for postpubertal females from all cultural and ethnic backgrounds. …”
    Get full text
    Article
  15. 495
  16. 496
  17. 497

    Breast Cancer Knowledge and Practice of Breast Self-Examination among Female University Students, Gaza by Samira S. Abo Al-Shiekh, Mohamed Awadelkarim Ibrahim, Yasser S. Alajerami

    Published 2021-01-01
    “…Breast cancer is the highest public detected cancer among female population in the majority of countries worldwide. …”
    Get full text
    Article
  18. 498
  19. 499

    Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status by Yue Qiu, Yaqin Shi, Zhujun Chao, Xinyu Zhu, Yan Chen, Linlin Lu

    Published 2025-01-01
    “…Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. …”
    Get full text
    Article
  20. 500

    Dysfunction of Thyroid and Parathyroid After Breast Cancer Radiation Therapy in Bandarabbas Omid Radiotherapy Center by Yaghoub Ashouri Taziani, Ramie Derakhshande, Leili Darvish, Mahdieh Afkhami Ardekani, Jahanbakhsh Bagherzadeh Homaei, Parisa Rabiei, Mohammad Haghparast

    Published 2024-12-01
    “…Background: Radiotherapy-induced hypothyroidism (HT) seems to be more frequent in breast cancer (BC) patients receiving radiotherapy to the supraclavicular field because part of the thyroid gland is included in the field. …”
    Get full text
    Article